Molecular Devices introduces a new assay kit for high throughput screening of oncology drug targets, the Flipr Calcium Plus, for use with 384-well plate systems Molecular De
Molecular Devices has announced the launch of the Flipr Calcium Plus assay kit.
This kit extends the use of Molecular Devices' flagship Fluorometric Imaging Plate Reader (Flipr) system to address difficult drug targets, such as chemokine receptors, in a 384-well plate format compatible with high-throughput screening.
Cell-based screening is a preferred technique in drug discovery because it generates leads with a higher probability of progressing to clinical trials.
Calcium flux assays are the most important cell-based screen and all of the major pharmaceutical companies use Molecular Devices' Flipr system for calcium flux assays.
However, some targets, such as chemokines, do not generate reliable results in traditional assay formats.
With the new Calcium Plus assay kit, the Flipr system generates data from chemokine targets that could not previously be screened in high-throughput live-cell assays. "Chemokine targets are particularly important in cancer research and have proved difficult to address using standard techniques," stated Stephen Oldfield marketing director for drug discovery at Molecular Devices.
"This kit provides a robust assay for chemokine targets in an HTS format - our beta sites screened targets that they couldn't screen before." "Flipr has been most heavily used in the CNS and cardiovascular areas, whereas this kit increases its utility in the oncology laboratory," Oldfield continued.
"The Calcium Plus assay kit is also formulated for Molecular Devices' Flexstation system providing product solutions for assay development and hit-to-lead stages in the drug discovery pipeline."
